As our study demonstrated that co-administration of WY-14643 and BI-9564 decreases plasma NEFA levels (Fig. 6I), co-administration of a PPARα agonist and BI-9564 has the potential to suppress the progression of MASLD and MASH. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.